NFKB1 and Miyoshi myopathy: One of the most important game-changer drugs in MM was proteasome inhibitor bortezomib, owing to its various anti-myeloma effects including disruption of the cell cycle and induction of apoptosis, alteration of the bone marrow microenvironment and inhibition of nuclear factor kappa B (NFκB).